FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2955717537> ?p ?o ?g. }

• W2955717537 endingPage "2384" @default.
• W2955717537 startingPage "2384" @default.
• W2955717537 abstract "Abstract Advances in the treatment of multiple myeloma have been driven by the development of new modalities, including proteasome inhibitors, immunomodulatory agents and monoclonal antibodies. TAK-169 is an engineered toxin body (ETB) comprising a proprietarily engineered, deimmunized form of the ribosome inactivating Shiga-like toxin A-subunit (SLTA) genetically fused to an antibody fragment that specifically targets the CD38 cell surface receptor. Although CD38 is a poorly internalizing receptor, TAK-169 is able to efficiently internalize and directly kill CD38-expressing cells through the enzymatic and irreversible inhibition of protein synthesis. This novel mechanism of action may be relevant in patients who have progressed after or are unlikely to respond to CD38-targeted antibody therapy. A library of unique CD38-targeting antibodies fused to deimmunized SLTA was screened in a variety of efficacy and safety models to identify TAK-169. TAK-169 demonstrated potent cytotoxicity across a range of myeloma cell lines with a range of CD38 expression in vitro as well as in patient-derived samples including with previous exposure to daratumumab. TAK-169 retains activity in whole blood and PBMCs, indicating that the presence of red blood cells is not restrictive to cytotoxicity. Furthermore, TAK-169 retains activity in the presence of excess approved, CD38 targeted therapeutic daratumumab. TAK-169 is efficacious in several myeloma xenograft models, both subcutaneous and disseminated. Complete regressions were observed using both a once-weekly and bi-weekly schedule. In addition, a syngeneic model cell line expressing human CD38 was shown to be responsive to TAK-169 treatment in an immunocompetent mouse model, suggesting the possibility of immune mediated cell death induced by TAK-169. Tolerability studies in non-human primates demonstrate that repeat administration is tolerated at doses expected to be efficacious. Takeda Pharmaceuticals and Molecular Templates jointly discovered TAK-169 and are co-developing the molecule for the treatment of multiple myeloma. TAK-169 is expected to enter clinical studies in 2019. Citation Format: Erin K. Willert, Garrett L. Robinson, Jack P. Higgins, Jensing Liu, Janice Lee, Sakeena Syed, Yuhong Zhang, Dan Tavares, Anya Lublinsky, Nibedita Chattopadhyay, Haiqing Wang, Laura Packer, Pu Shi, Carole Harbison, Sanjay Patel, John Newcomb. TAK-169, an exceptionally potent CD38 targeted engineered toxin body, as a novel direct cell kill approach for the treatment of multiple myeloma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 2384." @default.
• W2955717537 created "2019-07-12" @default.
• W2955717537 creator A5000118493 @default.
• W2955717537 creator A5010779246 @default.
• W2955717537 creator A5014825033 @default.
• W2955717537 creator A5016098920 @default.
• W2955717537 creator A5016328953 @default.
• W2955717537 creator A5024517976 @default.
• W2955717537 creator A5027266596 @default.
• W2955717537 creator A5036886971 @default.
• W2955717537 creator A5054564078 @default.
• W2955717537 creator A5062632577 @default.
• W2955717537 creator A5062871565 @default.
• W2955717537 creator A5065754893 @default.
• W2955717537 creator A5067829402 @default.
• W2955717537 creator A5087922064 @default.
• W2955717537 creator A5088339737 @default.
• W2955717537 creator A5088486032 @default.
• W2955717537 date "2019-07-01" @default.
• W2955717537 modified "2023-09-25" @default.
• W2955717537 title "Abstract 2384: TAK-169, an exceptionally potent CD38 targeted engineered toxin body, as a novel direct cell kill approach for the treatment of multiple myeloma" @default.
• W2955717537 doi "https://doi.org/10.1158/1538-7445.am2019-2384" @default.
• W2955717537 hasPublicationYear "2019" @default.
• W2955717537 type Work @default.
• W2955717537 sameAs 2955717537 @default.
• W2955717537 citedByCount "11" @default.
• W2955717537 countsByYear W29557175372020 @default.
• W2955717537 countsByYear W29557175372021 @default.
• W2955717537 countsByYear W29557175372022 @default.
• W2955717537 countsByYear W29557175372023 @default.
• W2955717537 crossrefType "journal-article" @default.
• W2955717537 hasAuthorship W2955717537A5000118493 @default.
• W2955717537 hasAuthorship W2955717537A5010779246 @default.
• W2955717537 hasAuthorship W2955717537A5014825033 @default.
• W2955717537 hasAuthorship W2955717537A5016098920 @default.
• W2955717537 hasAuthorship W2955717537A5016328953 @default.
• W2955717537 hasAuthorship W2955717537A5024517976 @default.
• W2955717537 hasAuthorship W2955717537A5027266596 @default.
• W2955717537 hasAuthorship W2955717537A5036886971 @default.
• W2955717537 hasAuthorship W2955717537A5054564078 @default.
• W2955717537 hasAuthorship W2955717537A5062632577 @default.
• W2955717537 hasAuthorship W2955717537A5062871565 @default.
• W2955717537 hasAuthorship W2955717537A5065754893 @default.
• W2955717537 hasAuthorship W2955717537A5067829402 @default.
• W2955717537 hasAuthorship W2955717537A5087922064 @default.
• W2955717537 hasAuthorship W2955717537A5088339737 @default.
• W2955717537 hasAuthorship W2955717537A5088486032 @default.
• W2955717537 hasConcept C10205521 @default.
• W2955717537 hasConcept C109316439 @default.
• W2955717537 hasConcept C115085202 @default.
• W2955717537 hasConcept C159654299 @default.
• W2955717537 hasConcept C159912055 @default.
• W2955717537 hasConcept C185592680 @default.
• W2955717537 hasConcept C202751555 @default.
• W2955717537 hasConcept C203014093 @default.
• W2955717537 hasConcept C2776364478 @default.
• W2955717537 hasConcept C2781119759 @default.
• W2955717537 hasConcept C28328180 @default.
• W2955717537 hasConcept C502942594 @default.
• W2955717537 hasConcept C542903549 @default.
• W2955717537 hasConcept C55493867 @default.
• W2955717537 hasConcept C71924100 @default.
• W2955717537 hasConcept C86803240 @default.
• W2955717537 hasConcept C95444343 @default.
• W2955717537 hasConcept C98274493 @default.
• W2955717537 hasConceptScore W2955717537C10205521 @default.
• W2955717537 hasConceptScore W2955717537C109316439 @default.
• W2955717537 hasConceptScore W2955717537C115085202 @default.
• W2955717537 hasConceptScore W2955717537C159654299 @default.
• W2955717537 hasConceptScore W2955717537C159912055 @default.
• W2955717537 hasConceptScore W2955717537C185592680 @default.
• W2955717537 hasConceptScore W2955717537C202751555 @default.
• W2955717537 hasConceptScore W2955717537C203014093 @default.
• W2955717537 hasConceptScore W2955717537C2776364478 @default.
• W2955717537 hasConceptScore W2955717537C2781119759 @default.
• W2955717537 hasConceptScore W2955717537C28328180 @default.
• W2955717537 hasConceptScore W2955717537C502942594 @default.
• W2955717537 hasConceptScore W2955717537C542903549 @default.
• W2955717537 hasConceptScore W2955717537C55493867 @default.
• W2955717537 hasConceptScore W2955717537C71924100 @default.
• W2955717537 hasConceptScore W2955717537C86803240 @default.
• W2955717537 hasConceptScore W2955717537C95444343 @default.
• W2955717537 hasConceptScore W2955717537C98274493 @default.
• W2955717537 hasIssue "13_Supplement" @default.
• W2955717537 hasLocation W29557175371 @default.
• W2955717537 hasOpenAccess W2955717537 @default.
• W2955717537 hasPrimaryLocation W29557175371 @default.
• W2955717537 hasRelatedWork W2000578943 @default.
• W2955717537 hasRelatedWork W2039167915 @default.
• W2955717537 hasRelatedWork W2049463037 @default.
• W2955717537 hasRelatedWork W2067077431 @default.
• W2955717537 hasRelatedWork W2369078388 @default.
• W2955717537 hasRelatedWork W2443772760 @default.
• W2955717537 hasRelatedWork W2588049026 @default.
• W2955717537 hasRelatedWork W3015905343 @default.
• W2955717537 hasRelatedWork W3032886263 @default.
• W2955717537 hasRelatedWork W4223493498 @default.
• W2955717537 hasVolume "79" @default.

• next